Highlights Vigil Neuroscience, Inc.

Equities

VIGL

US92673K1088

Market Closed - Nasdaq Other stock markets 03:59:47 2024-05-29 pm EDT			5-day change	1st Jan Change
2.955 ^USD	-10.73%		-19.70%	-12.57%

May. 07	Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 17	Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	Apr. 17	CI
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Vigil Neuroscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26	CI
Vigil Neuroscience Reports Positive Interm Results for Treatment of Axonal Spheroids and Pigmented Glia	Nov. 16	MT
Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE	Nov. 16	CI
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease	23-10-17	CI
Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927	23-10-12	CI
Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP	23-09-26	CI
Vigil Neuroscience, Inc. Presents VGL101 Complete Phase 1 Data and Phase 2 Ignite Trial Design at the 2023 American Neurological Association Annual Meeting	23-09-11	CI
Ververv Neuroscience, Inc. Receives Notification from the U.S. Food and Drug Administration Regarding Its Investigational New Drug Application to Evaluate the Company's Oral Small Molecule Trem2 Agonist Vv-3927	23-09-08	CI
Vigil Neuroscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia	23-05-08	CI
Vigil Neuroscience Says FDA Lifts Partial Clinical Hold on VGL101	23-03-30	MT
Vigil Neuroscience, Inc. Announces FDA Lifted the Partial Clinical Hold on VGL101	23-03-30	CI
Vigil Neuroscience's Q4 Loss Narrows	23-03-21	MT
VIGIL NEUROSCIENCE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-21	AQ
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vigil Neuroscience, Inc.

Equities

VIGL

US92673K1088

Highlights

Filters